Skip to main content Back to Top


Dexrazoxane Injection

Products Affected - Description

    • Zinecard injection, Pfizer, 500 mg, vial, 1 count, NDC 00013-8727-89

Reason for the Shortage

    • Cumberland Pharmaceuticals relaunched Totect in late-July 2017.
    • Fosun Pharma has dexrazoxane available.
    • Hikma has dexrazoxane available.
    • Mylan Institutional has dexrazoxane available.
    • Pfizer states manufacturing delay as the reason for the shortage.

Available Products

    • Totect kit, Cumberland Pharmaceuticals, 500 mg, vial, (only for extravasation injuries) 1 count, NDC 66220-0110-01
    • Zinecard injection, Pfizer, 250 mg, vial, 1 count, NDC 00013-8717-62
    • Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01
    • Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01
    • Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01
    • Dexrazoxane injection, Mylan Institutional, 250 mg, vial, 1 count, NDC 67457-0207-25
    • Dexrazoxane injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0208-50

Estimated Resupply Dates

    • Pfizer has Zinecard 500 mg vials on back order and the company estimates a release date of December 2019.


Updated November 13, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins